Statistiche di base
| LEI | 529900Z3CEEEN7U9B668 |
| CIK | 1771885 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to FSD Pharma Inc
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 21, 2025 |
Quantum BioPharma Announces Corporate Updates EXHIBIT 99.1 Quantum BioPharma Announces Corporate Updates TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of p |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of p |
|
| August 11, 2025 |
EXHIBIT 99.1 Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated t |
|
| August 8, 2025 |
EXHIBIT 99.1 Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of p |
|
| August 7, 2025 |
Exhibit 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and six months ended June 30, 2025, and 2024 [expressed in United States dollars] F-1 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [unaudited] [expressed in United States dollars] As at June 30, Decem |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2025 Commission File Number: 001-39152 Quantum Biopharma Ltd. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of princi |
|
| August 7, 2025 |
EXHIBIT 99.1 Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt Unprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum |
|
| August 7, 2025 |
Exhibit 99.2 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (this “MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “Quantum”, “Quantum BioPharma”, “we”, “us” or “o |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of p |
|
| August 5, 2025 |
EXHIBIT 99.1 Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS) TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of p |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of p |
|
| August 4, 2025 |
EXHIBIT 99.1 Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing TORONTO, Aug. 04, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portf |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| July 31, 2025 |
EXHIBIT 99.1 Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO This Offering Will Not Dilute Quantum BioPharma Shareholders TORONTO, July 31, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative ass |
|
| July 22, 2025 |
Quantum BioPharma Makes Strategic Investment in GameStop Corp. EXHIBIT 99.1 Quantum BioPharma Makes Strategic Investment in GameStop Corp. TORONTO, July 22, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| July 8, 2025 |
EXHIBIT 99.1 Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom TORONTO, July 08, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, to |
|
| June 27, 2025 |
Quantum BioPharma Announces Private Placement EXHIBIT 99.1 Quantum BioPharma Announces Private Placement TORONTO, June 27, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A mu |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| June 26, 2025 |
EXHIBIT 99.1 Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise TORONTO, June 26, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a b |
|
| June 17, 2025 |
EXHIBIT 99.1 Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 TORONTO, June 17, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quan |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2025 Commission File Number: 001-39152 Quantum Biopharma Ltd. (Translation of registrant’s name into English) 55 University Avenue, Suite 1003, Toronto, Ontario M5J 2H7 |
|
| June 16, 2025 |
Exhibit 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three months ended March 31, 2025, and 2024 [expressed in United States dollars] F-1 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [unaudited] [expressed in United States dollars] As at March 31, December 31 |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| June 13, 2025 |
EXHIBIT 99.1 Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds TORONTO, June 13, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| June 10, 2025 |
EXHIBIT 99.1 Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000 TORONTO, June 10, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased additional Bitcoin (BT |
|
| June 3, 2025 |
Quantum BioPharma Clarifies It Has Not Changed Its Name EXHIBIT 99.1 Quantum BioPharma Clarifies It Has Not Changed Its Name TORONTO, June 03, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misin |
|
| June 3, 2025 |
6-K 1 f6k060325.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M |
|
| May 30, 2025 |
EXHIBIT 99.1 Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years TORONTO, May 30, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 29, 2025 |
EXHIBIT 99.1 Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc. TORONTO, May 29, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biote |
|
| May 28, 2025 |
EXHIBIT 99.1 Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome TORONTO, May 28, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 21, 2025 |
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets EXHIBIT 99.1 Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets TORONTO, May 21, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has selected BitGo Trust Compan |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 20, 2025 |
EXHIBIT 99.1 Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis TORONTO, May 20, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 19, 2025 |
EXHIBIT 99.1 Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000 TORONTO, May 19, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that a |
|
| May 16, 2025 |
EXHIBIT 99.1 Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference TORONTO, May 16, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”) a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management w |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2025 Commission File Number: 001-39152 Quantum Biopharma Ltd. (Translation of registrant's name into English) 55 University Avenue, Suite 1003, Toronto, Ontario M5J 2H7, Canada (Address of |
|
| May 14, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Donal Carroll, the Chief Financial Officer of Quantum Biopharma Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Quantum Biopharma Ltd. (the “issuer”) for the interim period ended March 31, 2025. 2. No misrepresentations: Based on |
|
| May 14, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Zeeshan Saeed, the Chief Executive Officer of Quantum Biopharma Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Quantum Biopharma Ltd. (the “issuer”) for the interim period ended March 31, 2025. 2. No misrepresentations: Based on |
|
| May 14, 2025 |
Exhibit 99.2 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (this “MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “Quantum”, “Quantum BioPharma”, “we”, “us” or “o |
|
| May 14, 2025 |
Exhibit 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three months ended March 31, 2025, and 2024 [expressed in United States dollars] F-1 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [unaudited] [expressed in United States dollars] As at March 31, December 31 |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 12, 2025 |
EXHIBIT 99.1 Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis TORONTO, May 12, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of prin |
|
| May 5, 2025 |
EXHIBIT 99.1 Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing To assist enquiries a copy of the amended complaint can be viewed by clicking the following link: Quantum Amended Court Claim TORONTO, May 05, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Lt |
|
| April 24, 2025 |
EXHIBIT 99.1 Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time TORONTO, April 24, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announced it will host a Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern time to discuss its recent |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| April 22, 2025 |
EXHIBIT 99.1 Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor TORONTO, April 22, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| April 21, 2025 |
Quantum BioPharma Corporate Update Quantum BioPharma Corporate Update Toronto, Ontario - April 18, 2025 - Quantum BioPharma Ltd. |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| April 14, 2025 |
EXHIBIT 99.1 Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due TORONTO, April 14, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to buil |
|
| April 10, 2025 |
EXHIBIT 99.1 Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™ TORONTO, April 10, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nut |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| April 3, 2025 |
EXHIBIT 99.1 Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region TORONTO, April 03, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announ |
|
| April 1, 2025 |
EXHIBIT 99.1 Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis TORONTO, April 01, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| March 31, 2025 |
EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F/A of Quantum BioPharma Ltd. (the "Company") for the period ended December 31, 2024, (the "Report"), I, Zeeshan Saeed, Chief Executive Officer, President and Co-Executive Chairman of the Company, certify, pursuant to 18 U.S.C. |
|
| March 31, 2025 |
EXHIBIT 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F/A of Quantum BioPharma Ltd. (the "Company") for the period ended December 31, 2024,(the "Report"), I, Nathan Coyle, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section |
|
| March 31, 2025 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXHIBIT 12.1 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Zeeshan Saeed, certify that: 1. I have reviewed this annual report on Form 20-F/A of Quantum BioPharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumsta |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O |
|
| March 31, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated March 27, 2025 with respect to the consolidated financial statements of Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, and for each of the years in the three-year period ended December 31, 2024, included in this Amendment N |
|
| March 31, 2025 |
EXHIBIT 99.1 Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms TORONTO, March 31, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final tranche (“Final Tranche”) of the offering announced on December 5, 2024 (the |
|
| March 31, 2025 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXHIBIT 12.2 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Donal Carroll certify that: 1. I have reviewed this annual report on Form 20-F/A of Quantum BioPharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstan |
|
| March 28, 2025 |
EXHIBIT 4.23 [UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY (OR THE CLASS B SHARES ISSUABLE ON CONVERSION THEREOF) BEFORE [●]] THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AME |
|
| March 28, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Quantum BioPharma Ltd. (the "Company") for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Nathan Coyle, Chief Financial Officer of the Company |
|
| March 28, 2025 |
EXHIBIT 4.22 SHAREHOLDERS AGREEMENT BETWEEN: Fortius Research and Trading Corp. - and - Xorax Family Trust - and - Quantum BioPharma Ltd. 1 TABLE OF CONTENTS ARTICLE I PRELIMINARY MATTERS. 4 1.1 Recitals. 4 1.2 Prior Agreements. 4 ARTICLE II DEFINITIONS AND RULES OF INTERPRETATION.. 4 2.1 Definitions. 4 2.2 Rules of Interpretation. 8 2.3 Entire Agreement 9 2.4 Applicable Law.. 9 ARTICLE III TRANSF |
|
| March 28, 2025 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Except as otherwise stated, the information in this Description of Securities is provided as of the date of the Annual Report. The following summary does not purport to be complete. The summary is subject to and qualified by the Articles of Amalgamation of Quantum BioPharma Ltd. dated November 1, 1998, as amended though the date of the Annual Report (“Articles |
|
| March 28, 2025 |
INSIDER TRADING AND BLACKOUT PERIOD POLICY Effective as of and from March 30, 2023 EXHIBIT 11.1 INSIDER TRADING AND BLACKOUT PERIOD POLICY Effective as of and from March 30, 2023 - 1 - FSD PHARMA INC. INSIDER TRADING AND BLACKOUT PERIOD POLICY 1.0 PURPOSE FSD Pharma Inc. (the “Company”) believes its employees, officers and directors may consider becoming shareholders of the Company on a long-term investment basis, if such an investment is appropriate for that individual.1 Since |
|
| March 28, 2025 |
QUANTUM BIOPHARMA LTD. CLAWBACK POLICY EXHIBIT 97.1 QUANTUM BIOPHARMA LTD. CLAWBACK POLICY This Quantum BioPharma Ltd. Clawback Policy (this “Policy”) was approved effective as of November 28, 2023 (the “Effective Date”) by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Quantum BioPharma Ltd. (the “Company”). This Policy is adopted pursuant to and intended to comply with Rule 5608 (Recovery of E |
|
| March 28, 2025 |
EXHIBIT 15.2 |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 28, 2025 |
EXHIBIT 2.2 Exhibit A-1 EXHIBIT “A” FORM OF DEBENTURE CERTIFICATE CONVERTIBLE DEBENTURE CERTIFICATE QUANTUM BIOPHARMA LTD. (Incorporated under the laws of the Province of British Columbia) DEBENTURE CERTIFICATE NO. 20-12-00[●] PRINCIPAL AMOUNT: $ Quantum Biopharma Ltd. of 55 University Avenue, Suite 1003, Toronto, Ontario, M5J 2H7 (the “Company”), for value received, hereby acknowledges itself ind |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| March 28, 2025 |
EXHIBIT 15.1 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (this “MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “Quantum”, “Quantum BioPharma”, “we”, “us” or “o |
|
| March 28, 2025 |
EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Quantum BioPharma Ltd. (the "Company") for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Zeeshan Saeed, Chief Executive Officer, President an |
|
| March 28, 2025 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXHIBIT 12.2 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Donal Carroll certify that: 1. I have reviewed this annual report on Form 20-F of Quantum BioPharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance |
|
| March 28, 2025 |
EXHIBIT 4.24 GENERAL SECURITY AGREEMENT THIS GENERAL SECURITY AGREEMENT (as amended, modified, supplemented, restated or replaced from time to time, this “Agreement”), dated as of [●], made by and between Quantum Biopharma Ltd., a corporation existing under the laws of Ontario (the “Obligor”), in favor of [●] (the “Secured Party”). WHEREAS the Obligor has received signed subscription agreements an |
|
| March 28, 2025 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXHIBIT 12.1 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Zeeshan Saeed, certify that: 1. I have reviewed this annual report on Form 20-F of Quantum BioPharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| March 28, 2025 |
EXHIBIT 2.3 EXHIBIT “B” FORM OF WARRANT CERTIFICATE THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UND |
|
| March 28, 2025 |
AGENCY AND INTERLENDER AGREEMENT EXHIBIT 4.24 AGENCY AND INTERLENDER AGREEMENT THIS AGENCY AND INTERLENDER AGREEMENT (as amended, restated or otherwise modified from time to time, this “Agreement”) dated as of [●]. AMONG: [●]. having an address [●] (the “Agent”) AND: Quantum Biopharma Ltd., having its domicile at 55 University Avenue, Suite 1003, Toronto, Ontario, M5J 2H7 (the “Company”) AND: THE HOLDERS LISTED ON SCHEDULE “A” AT |
|
| March 28, 2025 |
EXHIBIT 99.1 Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern Completion of unbuzzd™ Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company’s Pipeline of Products and Assets TORONTO, March 28, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma |
|
| March 27, 2025 |
EXHIBIT 99.1 Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors TORONTO, March 27, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be repl |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| March 26, 2025 |
EXHIBIT 99.1 Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales New Ultra-Portable unbuzzd™ Single-Use Powder Sticks in Convenient 8-Pack Display Boxes Now Available for US Retailers TORONTO, March 26, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced i |
|
| March 20, 2025 |
EXHIBIT 99.1 Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies TORONTO, March 20, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pr |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of |
|
| February 26, 2025 |
EXHIBIT 99.1 Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 Safety Review Committee Found No Safety Concerns Following Milestone Trial TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced t |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of |
|
| February 18, 2025 |
EXHIBIT 99.1 Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company h |
|
| February 11, 2025 |
EXHIBIT 99.1 Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today ann |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of |
|
| February 10, 2025 |
EXHIBIT 99.1 Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotec |
|
| February 10, 2025 |
6-K 1 f6k021025.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontar |
|
| February 6, 2025 |
EXHIBIT 99.1 Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) - BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical com |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of |
|
| February 4, 2025 |
EXHIBIT 99.1 Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPh |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39152 Quantum BioPharma Ltd. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: January 2025 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J 2H7, Canada (Address o |
|
| January 21, 2025 |
FORM 7 MONTHLY PROGRESS REPORT EXHIBIT 99.1 FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: Quantum BioPharma Ltd. (the "Issuer", or "Quantum") Trading Symbol: QNTM Number of Outstanding Listed Securities: 2,299,748 Date: January 7, 2025 (for the month of December 31, 2024) This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to repla |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGEACT OF 1934 For the month of: January 2025 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, OntarioM5J2H7, Canada (Address of princ |
|
| January 17, 2025 |
EXHIBIT 99.1 QUANTUM BIOPHARMA IN COURT WITH DR. RAZA BOKHARI ON JANUARY 24, 2025 SEEKING A COURT ORDER TO DECLARE HIM TO BE A VEXATIOUS LITIGANT AND OTHER LITIGATION UPDATES Awards in favour of Quantum BioPharma Total Approximately $3 Million Toronto, Ontario – January 17, 2025 – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), |
|
| January 14, 2025 |
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM EXHIBIT 99.1 Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM TORONTO, ON / ACCESSWIRE / January 14, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA: 0K91)(Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGEACT OF 1934 For the month of: January 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, OntarioM5J2H7, Canada (Address of princ |
|
| January 7, 2025 |
EXHIBIT 99.1 QUANTUM BIOPHARMA LTD. APPROVED TO DUAL LIST ON UPSTREAM Trading to become available January 14th under ‘QNTM’ Toronto, Ontario – January 7, 2025 – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becom |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGEACT OF 1934 For the month of: JANUARY 2025 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, OntarioM5J2H7, Canada (Address of princ |
|
| December 20, 2024 |
EXHIBIT 99.1 QUANTUM BIOPHARMA DIVERSIFIES TREASURY WITH THE PURCHASE OF USD $1,000,000 OF BITCOIN (BTC) AND OTHER CRYPTOCURRENCIES AND TO ALLOW FOR FUTURE FINANCINGS AND OTHER TRANSACTIONS IN CRYPTOCURRENCY Toronto, Ontario – December 20, 2024 – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approva |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGEACT OF 1934 For the month of: December 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, OntarioM5J2H7, Canada (Address of prin |
|
| November 25, 2024 |
EXHIBIT 99.1 Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGEACT OF 1934 For the month of: November 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, OntarioM5J2H7, Canada (Address of prin |
|
| November 12, 2024 |
EXHIBIT 99.2 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (this “MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “Quantum”, “we”, “us” or “our” refer to Quantum |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGEACT OF 1934 For the month of: November 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J2H7, Canada (Address of pri |
|
| November 12, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate EXHIBIT 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Donal Carroll, the Chief Financial Officer of Quantum Biopharma Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Quantum Biopharma Ltd. (the “issuer”) for the interim period ended September 30, 2024. 2. No misrepresentations: Base |
|
| November 12, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate EXHIBIT 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Zeeshan Saeed, the Chief Executive Officer of Quantum Biopharma Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Quantum Biopharma Ltd. (the “issuer”) for the interim period ended September 30, 2024. 2. No misrepresentations: Base |
|
| November 12, 2024 |
EXHIBIT 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and nine months ended September 30, 2024, and 2023 [unaudited] [expressed in United States dollars, except per share amounts] QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [Unaudited] [expressed in Uni |
|
| October 29, 2024 |
EXHIBIT 99.1 QUANTUM BIOPHARMA ANNOUNCES THAT SENTINEL DOSING HAS STARTED THE PHASE-1 MULTIPLE ASCENDING DOSE CLINICAL TRIAL FOR LUCID-21-302 (LUCID-MS) IN AUSTRALIA Toronto, ON – October 29, 2024 – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solu |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGEACT OF 1934 For the month of: October2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, OntarioM5J2H7, Canada (Address of princi |
|
| October 22, 2024 |
EXHIBIT 99.1 QUANTUM BIOPHARMA (NASDAQ: QNTM) POSTS LINK ON ITS WEBSITE TO ACCESS THE FILED COMPLAINT AGAINST CIBC WORLD MARKETS, RBC DOMINION SECURITIES AND OTHERS, SEEKING DAMAGES IN EXCESS OF $700,000,000 USD, FOR POSSIBLE STOCK PRICE MANIPULATION/SPOOFING To assist enquiries the copy of the complaint can be viewed by clicking the following link: Quantum Bio Pharma Complaint Toronto, ON – Octob |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: October 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Ave., Suite 1003 Toronto, Ontario M5J 2H7, Canada (Address o |
|
| October 21, 2024 |
EXHIBIT 99.1 QUANTUMBIOPHARMA (NASDAQ: QNTM) FILES A US FEDERAL LAWSUIT AGAINST CIBC WORLD MARKETS, RBC DOMINION SECURITIES AND OTHERS, SEEKING DAMAGES IN EXCESS OF $700,000,000 USD, FOR POSSIBLE STOCK PRICE MANIPULATION/SPOOFING Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipula |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: October 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 55 University Avenue, Suite 1003 Toronto, Ontario M5L 2H7, Canada (Address |
|
| October 7, 2024 |
EXHIBIT 99.1 Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America Toronto, ON – October 7, 2024 – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), provides an update by way of a news release issued by Celly Nutri |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: October 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of princ |
|
| September 30, 2024 |
QUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE EXHIBIT 99.1 QUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE Toronto, ON – September 27, 2024 – Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates. Option Grant The |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: September 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of pri |
|
| September 16, 2024 |
Quantum BioPharma Closes Private Placement Offering EXHIBIT 99.1 Quantum BioPharma Closes Private Placement Offering Toronto, September 13, 2024 Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that, further to its press release dated September 6, 2024 (the “September 6th Press Rele |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: September 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of pri |
|
| September 9, 2024 |
EXHIBIT 99.1 QUANTUM BIOPHARMA RECEIVES NASDAQ NOTIFICATION OF REGAINING COMPLIANCE WITH NASDAQ’S MINIMUM BID PRICE REQUIREMENT AND COMPLETES DEBT SETTLEMENTS Toronto, Ontario – September 6, 2024 - Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovat |
|
| September 9, 2024 |
EXHIBIT 99.1 Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis. TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovativ |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: September 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of pri |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: September 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of pri |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of princi |
|
| August 30, 2024 |
EXHIBIT 99.1 Quantum Biopharma announces Celly Nutrition Launches unbuzzd™ grab-and-go stick packs on Amazon.com so you can “own NOW and what’s NEXT”. Toronto, ON – August 30, 2024 – Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announ |
|
| August 27, 2024 |
EXHIBIT 4.2 INTELLECTUAL PROPERTY PURCHASE AGREEMENT This Agreement entered into as of October 2, 2023 B E T W E E N: LUCID PSYCHECEUTICALS INC. (hereinafter referred to as the "Vendor") OF THE FIRST PART; -and- CELLY NUTRITION CORPORATION (hereinafter referred to as the "Purchaser") OF THE SECOND PART; WHEREAS, the Vendor is the owner of the name and trademark “UNBUZZD”; AND, WHEREAS, the Purchas |
|
| August 27, 2024 |
Amendment No. 1 dated August 26, 2024 Filed pursuant to Rule 424(b)(5) to Prospectus Supplement dated February 16, 2024 Registration No. 333-276264 (To Prospectus dated January 4, 2024) QUANTUM BIOPHARMA LTD. (formerly known as FSD Pharma Inc.) Up to $2,235,601 Class B Subordinate Voting Shares This Amendment No. 1 (“Amendment”) amends certain information contained in our prospectus supplement, da |
|
| August 27, 2024 |
AMENDED AND RESTATED GENERAL SECURITY AGREEMENT EXHIBIT 4.4 AMENDED AND RESTATED GENERAL SECURITY AGREEMENT THIS AMENDED AND RESTATED GENERAL SECURITY AGREEMENT (as amended, modified, supplemented, restated or replaced from time to time, this “Agreement”), dated as of April 3, 2024, made by and between Celly Nutrition Corp., a corporation existing under the laws of the Province of British Columbia (the “Obligor”), in favor of FSD Pharma Inc. (t |
|
| August 27, 2024 |
EXHIBIT 4.3 LOAN AMENDING AGREEMENT THIS LOAN AMENDING AGREEMENT (this “Agreement”) is dated as of April 3, 2024 with an effective date of March 31, 2024, by and between CELLY NUTRITION CORP., a Borrower existing under the laws of the Province of British Columbia (the “Borrower”), and FSD PHARMA INC. a company incorporated under the laws of the province on Ontario. (the “Lender”). The Borrower and |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of princi |
|
| August 27, 2024 |
AMENDED AND RESTATED EXCLUSIVE INTELLECTUAL PROPERTY LICENSE AGREEMENT EXHIBIT 4.1 AMENDED AND RESTATED EXCLUSIVE INTELLECTUAL PROPERTY LICENSE AGREEMENT THIS AGREEMENT is made on August 14, 2024, BETWEEN FSD PHARMA INC., a corporation existing pursuant to the laws of the Province of Ontario and having an office located at 199 Bay Street, Suite 4000, Toronto, ON M5L 1A9 (“FSD”) AND CELLY NUTRITION CORP., a corporation existing pursuant to the laws of the Province of |
|
| August 26, 2024 |
QUANTUM BIOPHARMA ANNOUNCES INTENTION TO COMPLETE DEBT SETTLEMENTS AND PROVIDES CORPORATE UPDATE EX-99.1 2 fsdex991.htm PRESS RELEASE EXHIBIT 99.1 QUANTUM BIOPHARMA ANNOUNCES INTENTION TO COMPLETE DEBT SETTLEMENTS AND PROVIDES CORPORATE UPDATE Toronto, Ontario - August 23, 2024 - Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and |
|
| August 26, 2024 |
6-K 1 fsd6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment No.1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 Quantum Biopharma Ltd. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada |
|
| August 19, 2024 |
FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF EXHIBIT 99.2 FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (“MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “FSD”, “we”, “us” or “our” refer to FSD Pharma Inc., together with our subsidiaries, on |
|
| August 19, 2024 |
EXHIBIT 99.3 |
|
| August 19, 2024 |
EXHIBIT 99.4 |
|
| August 19, 2024 |
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION EXHIBIT 99.1 Quantum Biopharma Ltd. Condensed consolidated interim financial statements For the three and six months ended June 30, 2024 and 2023 [unaudited] [expressed in United States dollars, except per share amounts] Quantum Biopharma Ltd. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [Unaudited] [expressed in United States dollars] As at June 30, December 31, 2024 2023 Notes |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of princi |
|
| August 16, 2024 |
EXHIBIT 3.1 |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 QUANTUM BIOPHARMA LTD. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of princi |
|
| August 15, 2024 |
EXHIBIT 99.1 FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol “QNTM” Toronto, August 15, 2024 Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: •) (“Quantum BioPharma” or the “Company”), formerly FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to |
|
| August 14, 2024 |
EXHIBIT 99.4 |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exec |
|
| August 14, 2024 |
EXHIBIT 99.3 |
|
| August 14, 2024 |
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION EXHIBIT 99.1 FSD Pharma Inc. Condensed consolidated interim financial statements For the three and six months ended June 30, 2024 and 2023 [unaudited] [expressed in United States dollars, except per share amounts] FSD PHARMA INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [Unaudited] [expressed in United States dollars] As at June 30, December 31, 2024 2023 Notes $ $ ASSETS Cu |
|
| August 14, 2024 |
FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF EXHIBIT 99.2 FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (“MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “FSD”, “we”, “us” or “our” refer to FSD Pharma Inc., together with our subsidiaries, on |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exe |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exe |
|
| August 12, 2024 |
FSD Pharma Announces Share Consolidation and Name Change EXHIBIT 99.1 FSD Pharma Announces Share Consolidation and Name Change Toronto, August 9, 2024 FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to announce the proposed consolidation of its issued and outstanding class A multiple voting shares (“ |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exe |
|
| August 9, 2024 |
EXHIBIT 99.1 FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd™ Stick Packs this Month – Created by a World-Class Pharmaceutical Research & Development Team Toronto, ON – August 9, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), provides an update on its investment in Celly Nutrition Corp. (“Celly |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: July 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| July 30, 2024 |
EXHIBIT 99.1 July 23, 2024 3:34 PM FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders Toronto, Ontario-(Newsfile Corp. - July 23, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to announce today the |
|
| July 8, 2024 |
Notice of Availability of Proxy Materials for FSD PHARMA INC. Annual General and Special Meeting EXHIBIT 99.3 FSD PHARMA INC. Have questions about this notice? Call the Toll Free Number below, or email. Toll Free 1-844-682-5888 Email: [email protected] Notice of Availability of Proxy Materials for FSD PHARMA INC. Annual General and Special Meeting Meeting Date and Location: When: Monday, July 22, 2024 1:00 p.m. (Toronto/New York time) Where: Garfinkle Biderman LLP, 1 Adelaide Street East, |
|
| July 8, 2024 |
FSD Pharma Inc. (the “Company”) Request for Financial Statements EXHIBIT 99.6 FSD Pharma Inc. (the “Company”) Request for Financial Statements In accordance with Canadian Securities Administrator’s National Instrument 51-102 – Continuous Disclosure Obligations, registered and beneficial shareholders may elect annually to receive a copy of our annual financial statements and corresponding management discussion and analysis (“MD&A”) or interim financial statement |
|
| July 8, 2024 |
FORM 51-102F3 AMENDED AND RESTATED MATERIAL CHANGE REPORT EXHIBIT 99.1 FORM 51-102F3 AMENDED AND RESTATED MATERIAL CHANGE REPORT Note to Reader: This Amended and Restated Material Change Report is being filed to amend the disclosure in Section 5.1 of the Material Change Report of FSD Pharma Inc. (the “Company”) previously filed on December 7, 2023 (the “Original MCR”). This Amended and Restated Material Change Report is being filed to provide additional |
|
| July 8, 2024 |
Please Print Name of Appointed Proxy EXHIBIT 99.5 Voting Instruction Form ("VIF") Record Date: June 12, 2024 Control Number: Meeting Date: July 22, 2024 Proxy Deadline: July 18, 2024 Shares to Vote: ****************************************************************************************************************************************************************************************************** FSD PHARMA INC. (the "Company") The Com |
|
| July 8, 2024 |
FSD PHARMA FILES AMENDED AND RESTATED MATERIAL CHANGE REPORT EXHIBIT 99.2 FSD PHARMA FILES AMENDED AND RESTATED MATERIAL CHANGE REPORT Toronto, July 4, 2024 - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that it has filed an amended and restated its material change report dated December 7, 2023 |
|
| July 8, 2024 |
EXHIBIT 99.1 FSD PHARMA INC. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF THE SHAREHOLDERS TO BE HELD ON JULY 22, 2024 AND MANAGEMENT INFORMATION CIRCULAR DATED: JUNE 10, 2024 FSD PHARMA INC. 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general and special meeting of the shareholders (“Shareh |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: June 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| July 8, 2024 |
EXHIBIT 99.7 CERTIFICATE OF ABRIDGMENT Section 2.20 of National Instrument 54-101 - Communication with Beneficial Owners of Securities of a Reporting Issuer (“NI 54-101”) TO: ONTARIO SECURITIES COMMISSION AND TO: ALBERTA SECURITIES COMMISSION BRITISH COLUMBIA SECURITIES COMMISSION MANITOBA SECURITIES COMMISSION FINANCIAL AND CONSUMER SERVICES COMMISSION OFFICE OF THE SUPERINTENDENT OF SECURITIES S |
|
| July 8, 2024 |
Please Print Name of Appointed Proxy EXHIBIT 99.4 FSD Pharma Inc. (the "Company") Form of Proxy ("Proxy") Record Date: June 12, 2024 Control Number: Meeting Date: July 22, 2024 Proxy Deadline: July 18, 2024 Shares to Vote: ************************************************************************************************************************************************************************************************************ The Compa |
|
| July 8, 2024 |
FSD PHARMA INC. 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9 MEETING OF SHAREHOLDERS EXHIBIT 99.2 FSD PHARMA INC. 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9 NOTICEOFANNUALGENERALANDSPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general and special meeting of the shareholders (“Shareholders”) of FSD Pharma Inc. (the “Company”) will be held in person at the offices of Garfinkle Biderman LLP, 1 Adelaide Street East, Suite 801, Toronto Ontario M5C 2V9 on |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: July 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| June 28, 2024 |
FSD Pharma provides Corporate Update EXHIBIT 99.1 FSD Pharma provides Corporate Update Toronto, June 28, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update. Corporate Update FSD Pharma has retained the services of Totaligent, Inc. (“To |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: June 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| June 28, 2024 |
EXHIBIT 99.1 FSD Pharma, Inc. wins Final Judgment to Confirm Arbitration Award of $3,059,998 plus interest entered against Dr. Raza Bokhari, currently serving as Chairman and CEO of Medicus Pharma Ltd. Toronto, ON – June 28, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech so |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: June 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| June 27, 2024 |
EXHIBIT 99.1 FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia. Toronto, ON – June 27, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: June 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| June 13, 2024 |
EXHIBIT 99.1 FSD Pharma enters into an exclusive option agreement with the University of Southern California to evaluate novel dietary supplement technology for unbuzzd™ and other business applications. Toronto, ON – June 13, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech s |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: June 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: June 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| June 4, 2024 |
EXHIBIT 99.1 FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication Toronto, ON – June 4, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, t |
|
| May 31, 2024 |
EXHIBIT 99.1 FSD Pharma, Inc. wins Petition to Confirm Arbitration Awards entered against Dr. Raza Bokhari Totaling Over $3 million CAD, plus interest. Toronto, ON – May 31, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worl |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execut |
|
| May 28, 2024 |
EXHIBIT 99.1 FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication Toronto, ON – May 28, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confir |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execut |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 24, 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal ex |
|
| May 24, 2024 |
FSD Pharma Provides Corporate Update EXHIBIT 99.1 FSD Pharma Provides Corporate Update Toronto, ON – May 24, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it has entered into an investor relations services agreement with IR Agency LLC (the “Agency”) effe |
|
| May 16, 2024 |
FSD Pharma Provides Update on Celly Nu’s New Packaging for unbuzzd(TM) EXHIBIT 99.1 FSD Pharma Provides Update on Celly Nu’s New Packaging for unbuzzd(TM) TORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), its new packaging and logo of unbuzzd™ expected to launch this summer, an innovative beverage product that is scientif |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 16, 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal ex |
|
| May 15, 2024 |
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION EXHIBIT 99.1 FSD Pharma Inc. Condensed consolidated interim financial statements For the three months ended March 31, 2024, and 2023 [unaudited] [expressed in United States dollars, except per share amounts] 1 FSD PHARMA INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [Unaudited] [expressed in United States dollars] As at March 31, December 31, 2024 2023 Notes $ $ ASSETS Curre |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May, 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal execu |
|
| May 15, 2024 |
FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF EXHIBIT 99.2 FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (“MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “FSD”, “we”, “us” or “our” refer to FSD Pharma Inc., together with our subsidiaries, on |
|
| May 15, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate EXHIBIT 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Zeeshan Saeed, the Chief Executive Officer of FSD Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of FSD Pharma (the “issuer”) for the interim period ended March 31, 2024. 2. No misrepresentations: Based on my knowledge, havi |
|
| May 15, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate EXHIBIT 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Nathan Coyle, the Chief Financial Officer of FSD Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of FSD Pharma Inc. (the “issuer”) for the interim period ended March 31, 2024. 2. No misrepresentations: Based on my knowledge, |
|
| May 7, 2024 |
EXHIBIT 99.1 FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia Toronto, ON – May 7, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailme |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 30, 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 30, 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal |
|
| April 30, 2024 |
EXHIBIT 99.1 FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy ofunbuzzd™ in an Induced State of Alcohol Intoxication Toronto, ON – April 30, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” of the “Company”), a biopharmaceutical company dedicated to building |
|
| April 25, 2024 |
FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd™ EXHIBIT 99.1 FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd™ Toronto, ON – April 25, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), provides an update by way of a news release issued by Celly Nutrition Corp. (“Celly Nu”), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 22, 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal |
|
| April 22, 2024 |
FSD Pharma Provides Another Update on Celly Nu’s Anticipated Launch of unbuzzd™ EXHIBIT 99.1 FSD Pharma Provides Another Update on Celly Nu’s Anticipated Launch of unbuzzd™ Toronto, ON – April 22, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), provides an update by way of a news release issued by Celly Nutrition Corp. (“Celly Nu”), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 22, 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal |
|
| April 17, 2024 |
EXHIBIT 99.1 FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products Toronto, ON – April 17, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldw |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exec |
|
| April 16, 2024 |
FSD Pharma announces Filing of Year-End 2023 Results EXHIBIT 99.1 FSD Pharma announces Filing of Year-End 2023 Results Toronto, ON – March 28, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the filing of its Annual Report on Form 20-F |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: March 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exec |
|
| April 15, 2024 |
EXHIBIT 99.1 FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption Toronto, ON – April 15, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”), provides an update on its investment in Celly Nutrition Corp. (“Celly Nu”), a privately he |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exec |
|
| April 9, 2024 |
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency TORONTO-(BUSINESS WIRE)-APRIL 7, 2024-FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that on April 5, 202 |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay Street, Suite 4000 Toronto, Ontario M5L 1A9 (Address of principal executive |
|
| April 2, 2024 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Except as otherwise stated, the information in this Description of Securities is provided as of the date of the Annual Report. The Corporation's authorized share capital consists of an unlimited number of Class A Shares and an unlimited number of Class B Shares, each with no par value. As of March 28, 2024, there were 72 Class A Shares issued and outstanding a |
|
| April 2, 2024 |
EXHIBIT 4.4 WARRANT UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY OR THE SECURITIES ISSUED UPON THE EXERCISE OF THIS SECURITY BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE July 31, 2023. EXERCISABLE FOLLOWING THE DATE HEREOF AND PRIOR TO THE EXPIRY TIME (AS DEFINED BELOW) AT WHICH TIME THESE WARRANTS SHALL EXPIRE AND BE NULL AND VOID. |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 2, 2024 |
EXHIBIT 4.2 ARRANGEMENTAGREEMENT THIS ARRANGEMENT AGREEMENT (“Agreement”) is made as of the 4th day of October, 2023. BETWEEN: FSD PHARMA INC., a corporation incorporated pursuant to the laws of the Province of Ontario, Canada. (“FSD Pharma” or “Corporation”) - and - CELLY NUTRITION CORP., a corporation incorporated pursuant to the laws of the Province of British Columbia, Canada. (“Celly Nu”) WHE |
|
| April 2, 2024 |
EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of FSD Pharma Inc. (the "Company") for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Zeeshan Saeed, Chief Executive Officer, President and Co-Ex |
|
| April 2, 2024 |
EXHIBIT 1.2 AMENDED AND RESTATED BY-LAW NUMBER 1 A BY-LAW RELATING GENERALLY TO THE REGULATION OF THE BUSINESS AND AFFAIRS OF FSD PHARMA INC. TABLE OF CONTENTS Page ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Number, Gender and Headings 2 1.3 By-Law Subordinate to Other Documents 2 1.4 Computation of Time 2 ARTICLE 2 DIRECTORS 2 2.1 Notice of Meeting 2 2.2 Waiver of Notice 3 2.3 No Notice to |
|
| April 2, 2024 |
FSD PHARMA INC. CLAWBACK POLICY EXHIBIT 97.1 FSD PHARMA INC. CLAWBACK POLICY This FSD Pharma Inc. Clawback Policy (this “Policy”) was approved effective as of November 28, 2023 (the “Effective Date”) by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of FSD Pharma Inc. (the “Company”). This Policy is adopted pursuant to and intended to comply with Rule 5608 (Recovery of Erroneously Awarded Co |
|
| April 2, 2024 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THESECURITIES EXCHANGE ACT OF 1934 EXHIBIT 12.1 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THESECURITIES EXCHANGE ACT OF 1934 I, Zeeshan Saeed, certify that: 1. I have reviewed this annual report on Form 20-F of FSD Pharma Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under |
|
| April 2, 2024 |
EXHIBIT 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of FSD Pharma Inc. (the "Company") for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Nathan Coyle, Chief Financial Officer of the Company, certi |
|
| April 2, 2024 |
EXHIBIT 4.5 LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”) is made as of July 31, 2023 (the “Effective Date”). BETWEEN: CELLY NUTRITION CORP., a company incorporated under the laws of the Province of British Columbia, (the “Borrower”) AND FSD PHARMA INC., a company incorporated under the laws of the Province of Ontario (the “Lender”) RECITALS: A. The Lender has agreed to provide the Borrowe |
|
| April 2, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated March 28, 2024 with respect to the consolidated financial statements of FSD Pharma Inc. and its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and for each of the years in the three-year period ended December 31, 2023, which includes an explanatory paragraph relating to the Company |
|
| April 2, 2024 |
FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF EXHIBIT 15.1 FSD PHARMA INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (“MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “FSD”, “we”, “us” or “our” refer to FSD Pharma Inc., together with our subsidiaries, on |
|
| April 2, 2024 |
EXCLUSIVE INTELLECTUAL PROPERTY LICENSE AGREEMENT EXHIBIT 4.3 EXCLUSIVE INTELLECTUAL PROPERTY LICENSE AGREEMENT THIS AGREEMENT is made on July 31, 2023, BETWEEN FSD PHARMA INC., a corporation existing pursuant to the laws of the Province of Ontario and having an office located at [redacted for confidentiality purposes] (“FSD”) AND CELLY NUTRITION CORP., a corporation existing pursuant to the laws of the Province of British Columbia and having an |
|
| April 2, 2024 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THESECURITIES EXCHANGE ACT OF 1934 EXHIBIT 12.2 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THESECURITIES EXCHANGE ACT OF 1934 I, Nathan Coyle, certify that: 1. I have reviewed this annual report on Form 20-F of FSD Pharma Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: March 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant’s name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exec |
|
| March 27, 2024 |
EXHIBIT 99.1 FSD Pharma signs the agreement with iNGENu CRO to conduct a clinical study to assess the safety and pharmacokinetics of multiple ascending doses of Lucid-21-302 (Lucid-MS) in healthy adults Toronto, ON – March 27, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative as |
|
| March 11, 2024 |
EXHIBIT 99.1 FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd™ Toronto, ON – March 11, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwid |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: March 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exec |
|
| March 5, 2024 |
EXHIBIT 99.1 FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum Toronto, ON – March 5, 2024 – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative asset |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: March 2024 Commission File Number: 001-39152 FSD PHARMA INC. (Translation of registrant's name into English) 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal exec |
